Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Heart and Vessels
Erschienen in: Heart and Vessels 1/2012

01.01.2012 | Original Article

Hypocellularity and insufficient expression of angiogenic factors in implanted autologous bone marrow in patients with chronic critical limb ischemia

verfasst von: Masato Oda, Ken Toba, Kiminori Kato, Takuya Ozawa, Takao Yanagawa, Noboru Ikarashi, Tsugumi Takayama, Tomoyasu Suzuki, Haruo Hanawa, Masayoshi Masuko, Hironori Kobayashi, Yoshifusa Aizawa

Erschienen in: Heart and Vessels | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to identify the clinical parameters of absolutely poor-prognosis patients with chronic critical limb ischemia (AP-CLI). Sixteen no-option CLI patients with arteriosclerosis obliterans: ASO (nine) and non-ASO patients (seven) treated with bone marrow-mononuclear cell implantation (BMI) were analyzed. There were three AP-CLI patients (all ASO). The mRNA expression of several angiogenic factors in the implanted cells was analyzed in comparison with normal donor bone marrow. To observe the response of bone marrow components to hypoxia, normal bone marrow cells were cultured for 24 h in 2.5% O2, and mRNA expression of angiogenic factors were measured. AP-CLI patients exhibited extraordinary low bone marrow cellularity as well as the percentage of CD34-positive cells. Among angiogenic factors, only VEGF expression was maintained in response to HIF-1, while other factors such as HGF, Ang-1, PLGF, and SDF-1 decreased in the implanted bone marrow cells of the patients with CLI compared to normal bone marrow cells. HIF-1 and all of the five angiogenic factors increased in vitro in response to hypoxia. Thus it is highly likely that angiogenic factors except VEGF do not respond to chronic ischemia in bone marrow in vivo. An organ-protection system against tissue ischemia may be applied for acute hypoxia, but it may be insufficient for chronic ischemia.
Literatur
1.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 Suppl S:S5–S67
2.
Mautner GC, Mautner SL, Roberts WC (1992) Amounts of coronary arterial narrowing by atherosclerotic plaque at necropsy in patients with lower extremity amputation. Am J Cardiol 70:1147–1151PubMedCrossRef
3.
De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C (2009) Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 24:321–328PubMedCrossRef
4.
Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114–1123PubMed
5.
Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, Sawa Y, Matsuda H, Kaneda Y, Ogihara T (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44:203–209PubMedCrossRef
6.
Zeng R, Chen YC, Zeng Z, Liu WQ, Liu XX, Liu R, Qiang O, Li X (2010) Different angiogenesis effect of mini-TyrRS/mini-TrpRS by systemic administration of modified siRNAs in rats with acute myocardial infarction. Heart Vessels 25:324–332PubMedCrossRef
7.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef
8.
Isner JM, Asahara T (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103:1231–1236PubMedCrossRef
9.
Yla-Herttuala S, Alitalo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9:694–701PubMedCrossRef
10.
Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T (2001) Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103:897–903PubMedCrossRef
11.
Subramaniyam V, Waller EK, Murrow JR, Manatunga A, Lonial S, Kasirajan K, Sutcliffe D, Harris W, Taylor WR, Alexander RW, Quyyumi AA (2009) Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease. Am Heart J 158:53–60.e1
12.
Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators (2002) Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360:427–435
13.
Napoli C, Farzati B, Sica V, Iannuzzi E, Coppola G, Silvestroni A, Balestrieri ML, Florio A, Matarazzo A (2008) Beneficial effects of autologous bone marrow cell infusion and antioxidants/l-arginine in patients with chronic critical limb ischemia. Eur J Cardiovasc Prev Rehabil 15:709–718PubMedCrossRef
14.
Bartsch T, Brehm M, Zeus T, Kögler G, Wernet P, Strauer BE (2007) Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol 96:891–899PubMedCrossRef
15.
Fadini GP, Agostini C, Avogaro A (2010) Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 209:10–17PubMedCrossRef
16.
Oda M, Toba K, Ozawa T, Kato K, Yanagawa T, Ikarashi N, Takayama T, Suzuki T, Hanawa H, Fuse I, Nakata K, Narita M, Takahashi M, Aizawa Y (2010) Establishment of culturing system for ex vivo expansion of angiogenic immature erythroid cells, and its application for treatment of patients with chronic severe lower limb ischemia. J Mol Cell Cardiol 49:347–353PubMedCrossRef
17.
Oda M, Kato K, Toba K, Otaki K, Kitajima T, Ikarashi N, Yanagawa T, Higashimura M, Asami F, Isoda M, Ozawa T, Moriyama M, Hirono S, Okura Y, Hanawa H, Kodama M, Aizawa Y (2007) Prognostic factors for critical limb ischemia after autologous bone marrow implantation. J Cardiol 50:235–242PubMed
18.
Liguori A, Fiorito C, Balestrieri ML, Crimi E, Bruzzese G, Williams-Ignarro S, D’Amora M, Sommese L, Grimaldi V, Minucci PB, Giovane A, Farzati B, Ignarro LJ, Napoli C (2008) Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease. Eur J Haematol 80:258–264PubMedCrossRef
19.
Toba K, Hanawa H, Fuse I, Sakaue M, Watanabe K, Uesugi Y, Higuchi W, Takahashi M, Aizawa Y (2002) Difference in CD22 molecules in human B cells and basophils. Exp Hematol 30:205–211PubMedCrossRef
20.
Yoshida T, Hanawa H, Toba K, Watanabe H, Watanabe R, Yoshida K, Abe S, Kato K, Kodama M, Aizawa Y (2005) Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 68:278–288PubMedCrossRef
21.
Rey S, Semenza GL (2010) Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 86:236–242PubMedCrossRef
22.
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514PubMedCrossRef
23.
Fong GH (2009) Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 87:549–560PubMedCrossRef
24.
Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, Jin D, Takai S, Miyazaki M, Egashira K, Imada T, Iwasaka T, Matsubara H (2003) Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 93:980–989PubMedCrossRef
25.
Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patients with ischaemic limb. Lancet 348:370–374PubMedCrossRef
26.
Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108:1933–1938PubMedCrossRef
27.
Loges S, Schmids T, Carmeliet P (2009) “Antimyeloangiogenic” therapy for cancer by inhibiting PlGF. Clin Cancer Res 15:3648–3653PubMedCrossRef
28.
Sacramento CB, da Silva FH, Nardi NB, Yasumura EG, Baptista-Silva JC, Beutel A, de Campos RR, de Moraes JZ, Junior HS, Samoto VY, Borojevic R, Han SW (2010) Synergistic effect of vascular endothelial growth factor and granulocyte colony-stimulating factor double gene therapy in mouse limb ischemia. J Gene Med 12:310–319PubMed
29.
Moriya J, Minamino T, Tateno K, Shimizu N, Kuwabara Y, Sato Y, Saito Y, Komuro I (2009) Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Interv 2:245–254PubMedCrossRef
30.
Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF (2000) Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87:728–730PubMed
31.
Ozawa T, Toba K, Kato K, Minagawa S, Saigawa T, Hanawa H, Makiyama Y, Moriyama M, Honma K, Isoda M, Hasegawa G, Naito M, Takahashi M, Aizawa Y (2006) Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol 40:629–638PubMedCrossRef
32.
Tordjman R, Delaire S, Plouët J, Ting S, Gaulard P, Fichelson S, Roméo PH, Lemarchandel V (2001) Erythroblasts are a source of angiogenic factors. Blood 97:1968–1974PubMedCrossRef
33.
Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, Hashimoto S, Furukawa T, Nakamura Y, Hanawa H, Kodama M, Yoshimura N, Fujiwara H, Namura O, Sogawa M, Hayashi J, Aizawa Y (2004) Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 68:1189–1193PubMedCrossRef
34.
Suzuki H, Iso Y, Kusuyama T, Omori Y, Soda T, Sato T, Shoji M, Koba S, Geshi E, Katagiri T (2006) Neutrophil and erythroblast regulate the effects of bone marrow cell implantation. Eur J Clin Invest 36:65–66PubMedCrossRef
35.
Iso Y, Soda T, Sato T, Sato R, Kusuyama T, Omori Y, Shoji M, Koba S, Katagiri T, Kobayashi Y, Suzuki H (2010) Impact of implanted bone marrow progenitor cell composition on limb salvage after cell implantation in patients with critical limb ischemia. Atherosclerosis 209:167–172PubMedCrossRef
36.
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007PubMedCrossRef
37.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB; International Committee of Medical Journal Editors (2005) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation 111:1337–1338
Metadaten
Titel
Hypocellularity and insufficient expression of angiogenic factors in implanted autologous bone marrow in patients with chronic critical limb ischemia
verfasst von
Masato Oda
Ken Toba
Kiminori Kato
Takuya Ozawa
Takao Yanagawa
Noboru Ikarashi
Tsugumi Takayama
Tomoyasu Suzuki
Haruo Hanawa
Masayoshi Masuko
Hironori Kobayashi
Yoshifusa Aizawa
Publikationsdatum
01.01.2012
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2012
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-011-0125-5

Weitere Artikel der Ausgabe 1/2012

Heart and Vessels 1/2012 Zur Ausgabe

Case Report

Diffuse in-stent restenosis of CYPHER® stent due to hypersensitivity reaction confirmed by pathohistological findings

Original Article

Effects of age on hemodynamic changes after transcatheter closure of atrial septal defect: importance of ventricular diastolic function

Original Article

Nitric oxide effects depend on different mechanisms in different regions of the rat heart

Original Article

Endothelin-1 prolongs intracellular calcium transient decay in neonatal rat cardiac myocytes

Original Article

Complex anatomy surrounding the left atrial posterior wall: analysis with 3D computed tomography

Original Article

A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise